A

Ascendis Pharma AS

ASNDNASDAQHEALTHCARE
$227.28+1.27 (+0.56%)
Market closedPrev close $226.01

Price action

Daily adjusted bars

1signal overlaid
Prior signal1

Snapshot

Key stats

AV May 30
Market cap
$14.74B
P/E ratio
27.07
Forward P/E
13.32
Beta
0.48
52W range
$160.86 - $250.74
Dividend yield
--
Volume
4.87M
Sector
HEALTHCARE

Analyst

Consensus price target

Live

Current

$227.28

Target

$298.26

+70.98 (+31.2%) upside12mo horizon

AlphaYou verdict

Insider Cluster

LONGLive
17/ 100
WeakScore 17 / 100Issued Jun 2, 2026

C-suite + 1 other insiders bought $167K of ASND this 14d.

  • Smart money5.2/40
  • Fundamentals7.0/35
  • Technicals1.0/15
  • Macro3.3/10

Receipts

Recent signals for this ticker

  • LONGJun 2
    Insider Cluster

    C-suite + 1 other insiders bought $167K of ASND this 14d.

    Public Recommendation·Checkpoints pending
  • LONGMay 29
    Insider Buy

    Insider bought $95K of ASND this 14d.

    Public Recommendation·Checkpoints pending

Smart money

Insider, fund, and political flow

Live4 receipts
  • insider buy

    EVP & Chief Financial Officer SMITH SCOTT THOMAS bought $56K

    +167490.0
  • insider buy

    Director BIENAIME JEAN JACQUES bought $112K

    +223124.0
  • insider buy

    Director BIENAIME JEAN JACQUES bought $95K

    +190241.0
  • short interest change

    Short interest fell -22.5% as of 2026-04-30 (twice-monthly FINRA)

    +2.0

Top trader activity

Pending

Copy-trading signal layer from real US-equity operators. Wires in once the CopyTrading feed is mapped to US-stock tickers.

BTC Astro risk regime

Pending

Cross-asset risk timing overlay. Used as context only, never a primary stock source.

Reputation

Sources and actors behind this ticker

Source families

Actors and filers

No mature rows yet.

Checkpoint ledger

Public recommendation outcomes

Pending

No public recommendation checkpoints have landed for this ticker yet.

D7 appears first, then D15 and D30 as the call matures.

Each row is a public recommendation. Alpha columns compare the frozen issued price with SPY, QQQ, and sector ETF checkpoints when available.

Raw source coverage

Primary-source receipt chain

100.0%
Linked
3
Events
2
Signals
2
Recs
Source coverage3/3
SEC EDGAR Form 43/3 linked
Recent source events
  • SEC EDGAR Form 4

    INSIDER BUY · Jun 1· source

    raw linked
  • SEC EDGAR Form 4

    INSIDER BUY · Jun 1· source

    raw linked
  • SEC EDGAR Form 4

    INSIDER BUY · May 27· source

    raw linked

Fundamentals

Valuation, quality, growth

Live

Valuation

  • P/E27.07
  • Forward P/E13.32
  • P/S17.02
  • P/B25.62

Quality

  • Profit margin57.3%
  • Operating margin10.1%
  • ROE33.3%
  • ROA-0.6%

Growth

  • Revenue YoY--
  • Earnings YoY--
  • Beta0.48
  • Dividend yield--

Technicals

Trend, momentum, levels

Live

Trailing returns

  • 5d+1.10%
  • 20d-0.62%
  • 60d+0.52%

Trend vs SMAs

  • vs SMA50+0.14%
  • vs SMA200+0.40%

52w range position

$160.8674%$250.74

Computed from AV daily adjusted bars. No options-flow, IV, or order-book signals on this page yet.

Macro

Sector + regime context

Live
  • macro regime shift

    VIX 15.3 (low volatility) as of 2026-05-29

    +15.3
  • macro regime shift

    10y-2y spread 47bps (flattish) as of 2026-05-29

    +0.5
  • macro regime shift

    Industrial Production 102.5 (mild expansion) as of 2026-04-01

    +102.5
  • macro regime shift

    Initial claims 215,000 vs 26w mean (ratio 1.01, neutral)

    +1.0
  • macro regime shift

    CPI YoY 3.95% (hot vs Fed target)

    +4.0

Earnings

EPS beat / miss history

Pending

No stored earnings history for this ticker.

The AV EARNINGS sweep backfills 8+ quarters per coverage cycle.

Debate

Key issues

Live
  • Bullish view

    • EVP & Chief Financial Officer SMITH SCOTT THOMAS bought $56K
    • Director BIENAIME JEAN JACQUES bought $112K
    • Director BIENAIME JEAN JACQUES bought $95K
    • Short interest fell -22.5% as of 2026-04-30 (twice-monthly FINRA)

    Bearish view

    No receipts on this side yet.

Arguments are pulled from contributing receipts (Form 4 / 13F / fundamentals / macro) for this ticker. Each side carries the count of receipts behind it, not an analyst headline count.

Track record

Recommendation receipts

Pending

No D7 recommendation checkpoints landed for this ticker.

A receipt appears once a published signal hits its first walk-forward window.